Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ABOS
$2.76
$
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Next Earnings
2026-02-25
Beta
0.245
Average Volume
Market Cap
Last Dividend
CIK
0001576885
ISIN
US00509G2093
CUSIP
00509G209
CEO
Daniel J. O'Connell
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
61
IPO Date
2021-07-01
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Daniel Joseph Oconnell Sells 12,941 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock | Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,941 shares of the business's stock in a transaction on Friday, January 9th. The shares were sold at an average price of $1.76, for a total value of $22,776.16. Following the completion of the transaction, the chief executive officer owned 598,898 shares | Defense World | 2026-01-14 05:30:42 |
| Matt Zuga Sells 6,888 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock | Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $1.82, for a total transaction of $12,536.16. Following the completion of the sale, the chief financial officer owned 209,951 | Defense World | 2026-01-14 04:48:52 |
| Daniel Joseph Oconnell Sells 8,143 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock | Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 8,143 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $1.82, for a total transaction of $14,820.26. Following the transaction, the chief executive officer owned 611,839 shares of the company's stock, | Defense World | 2026-01-14 04:48:49 |
| Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of “Moderate Buy” from Brokerages | Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average | Defense World | 2026-01-11 05:24:52 |
| Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) | Acumen Pharmaceuticals (NASDAQ: ABOS - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Earnings and Valuation This table compares Acumen | Defense World | 2025-12-15 02:08:49 |
| Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts | Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year | Defense World | 2025-11-25 03:29:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-23 | 2026-01-23 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-07 | 2026-01-07 | View Filing |
| 424B5 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-10 | 2025-11-10 | View Filing |
| 3 | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-11-04 | 2025-11-04 | View Filing |
| SC 13G/A | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-07-15 | 2025-07-15 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 8-K | 2025-06-05 | 2025-06-05 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| ARS | 2025-04-23 | 2025-04-23 | View Filing |
| DEFA14A | 2025-04-23 | 2025-04-23 | View Filing |
| DEF 14A | 2025-04-23 | 2025-04-23 | View Filing |
| SC 13D/A | 2025-03-31 | 2025-03-31 | View Filing |
| S-8 | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-11-06 | 2024-11-06 | View Filing |
| 3 | 2024-11-06 | 2024-11-06 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 8-K | 2024-06-05 | 2024-06-05 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| EFFECT | 2024-04-25 | 2024-04-25 | View Filing |
| ARS | 2024-04-22 | 2024-04-22 | View Filing |
| DEFA14A | 2024-04-22 | 2024-04-22 | View Filing |
| DEF 14A | 2024-04-22 | 2024-04-22 | View Filing |
| S-3 | 2024-03-27 | 2024-03-27 | View Filing |
| S-8 | 2024-03-27 | 2024-03-27 | View Filing |
| 10-K | 2024-03-26 | 2024-03-26 | View Filing |
| 8-K | 2024-03-26 | 2024-03-26 | View Filing |
| 8-K | 2024-03-19 | 2024-03-19 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 100.98% | 1 | 698 | 0.06 | 0.13 | 86.67 |
| Swarm Intelligence Strategy | 77.74% | 1 | 717 | 0.04 | 0.09 | 63.43 |
| Larry Williams PercentR Strategy | 71.12% | 1.02 | 172 | 0.05 | 0.13 | 56.81 |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |